Pimobendan alleviates myocyte apoptosis and fibrosis associated with mitral regurgitation by targeting endoplasmic reticulum stress

Abstract

Background: Endoplasmic reticulum (ER) stress is an important factor in the development of numerous cardiovascular disorders; nevertheless, the association between ER stress and mitral regurgitation (MR) remains inadequately characterized. The molecular mechanism of pimobendan (PIMO) that contributes to the delay in congestive heart failure (CHF) in MR associated with apoptosis and fibrosis is still unclear. Our aim was to examine the impact of PIMO on ER stress, apoptosis, and fibrosis in a chronic MR rat model.

Methods: MR was surgically induced in 10 Sprague–Dawley rats, with 5 serving as sham operation controls. At 8 weeks postsurgery, the MR animals were randomly allocated into two groups: MR and MR + PIMO groups. PIMO was administered twice daily through oral gavage for 4 weeks, whereas the sham and MR groups were administered similar quantities of drinking water. Echocardiography was conducted before the delivery of PIMO as a baseline measure and at the end of the study. At the end of the investigation, hearts were procured for histopathological and ER stress evaluations.

Results: PIMO significantly maintained heart function and structural remodeling in the MR animals. PIMO significantly reduced MR-induced myocyte apoptosis (p = 0.044) and fibrosis (p = 0.002) by reducing the messenger RNA expression of genes associated with ER stress (GRP78 [glucose-regulated protein 78], ATF4 [activating transcription factor 4], and CHOP [C/ERP homologous protein]) compared to the MR group (p < 0.05, p < 0.01, and p < 0.001, respectively).

Conclusion: PIMO demonstrated cardioprotective benefits on heart function, myocyte apoptosis, and fibrosis by regulating ER stress in an MR-induced CHF rat model.

Keywords

apoptosis / endoplasmic reticulum (ER) stress / fibrosis / mitral regurgitation / mitral regurgitation rat model / pimobendan

References

[1] Keene BW, Atkins CE, Bonagura JD, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med. 2019;33:1127-1140.

[2] Nishimura RA, Otto CM, Bonow RO, et al. AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2017;70:252-289.

[3] Constant Dit Beaufils AL, Huttin O, Jobbe-Duval A, et al. Replacement myocardial fibrosis in patients with mitral valve prolapse: relation to mitral regurgitation, ventricular remodeling, and arrhythmia. Circulation. 2021;143:1763-1774.

[4] Piek A, de Boer RA, Sillje HH. The fibrosis-cell death axis in heart failure. Heart Fail Rev. 2016;21:199-211.

[5] Lin YW, Chen CY, Shih JY, et al. Dapagliflozin improves cardiac hemodynamics and mitigates arrhythmogenesis in mitral regurgitation-induced myocardial dysfunction. J Am Heart Assoc. 2021;10:e019274.

[6] Nonaka M, Morimoto S, Murayama T, et al. Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. Br J Pharmacol. 2015;172:2369-2382.

[7] Boonpala P, Saengklub N, Srikam S, et al. Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation. BMC Vet Res. 2023;19:130.

[8] Matsumori A, Nunokawa Y, Sasayama S. Pimobendan inhibits the activation of transcription factor NF-kappaB: a mechanism which explains its inhibition of cytokine production and inducible nitric oxide synthase. Life Sci. 2000;67:2513-2519.

[9] Tam AB, Mercado EL, Hoffmann A, Niwa M. ER stress activates NF-kappaB by integrating functions of basal IKK activity, IRE1 and PERK. PLoS One. 2012;7:e45078.

[10] Cao SS, Kaufman RJ. Unfolded protein response. Curr Biol. 2012;22:R622-R626.

[11] Prola A, Nichtova Z, Pires Da Silva J, et al. Endoplasmic reticulum stress induces cardiac dysfunction through architectural modifications and alteration of mitochondrial function in cardiomyocytes. Cardiovasc Res. 2019;115:328-342.

[12] Minamino T, Kitakaze M. ER stress in cardiovascular disease. J Mol Cell Cardiol. 2010;48:1105-1110.

[13] Boswood A, Haggstrom J, Gordon SG, et al. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: The EPIC study—a randomized clinical trial. J Vet Intern Med. 2016;30:1765-1779.

[14] Fuentes VL, Corcoran B, French A, et al. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. J Vet Intern Med. 2002;16:255-261.

[15] Saengklub N, Pirintr P, Nampimoon T, Kijtawornrat A, Chaiyabutr N. Short-term effects of sacubitril/valsartan on echocardiographic parameters in dogs with symptomatic myxomatous mitral valve disease. Front Vet Sci. 2021;8:700230.

[16] O'Grady MR, Minors SL, O'Sullivan ML, Horne R. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy. J Vet Intern Med. 2008;22:897-904.

[17] Wess G, Kresken JG, Wendt R, et al. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial. J Vet Intern Med. 2020;34:2232-2241.

[18] Pirintr P, Saengklub N, Boonpala P, Hamlin RL, Kijtawornrat A. Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs. BMC Vet Res. 2023;19:201.

[19] Endoh M. Mechanism of action of Ca²⁺ sensitizers—update 2001. Cardiovasc Drugs Ther. 2001;15:397-403.

[20] Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta. 2013;1833:3460-3470.

[21] Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr. 1989;2:358-367.

[22] Jungtanasomboon P, Nussaro S, Winwan H, et al. Vericiguat preserved cardiac function and mitochondrial quality in a rat model of mitral regurgitation. Life Sci. 2023;328:121929.

[23] Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101-1108.

[24] Kim KH, Kim YJ, Ohn JH, et al. Long-term effects of sildenafil in a rat model of chronic mitral regurgitation: benefits of ventricular remodeling and exercise capacity. Circulation. 2012;125:1390-1401.

[25] Pu M, Gao Z, Zhang X, et al. Impact of mitral regurgitation on left ventricular anatomic and molecular remodeling and systolic function: implication for outcome. Am J Physiol Heart Circ Physiol. 2009;296:H1727-H1732.

[26] Ren J, Bi Y, Sowers JR, Hetz C, Zhang Y. Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases. Nat Rev Cardiol. 2021;18:499-521.

[27] Chen X, Guo X, Ge Q, et al. ER stress activates the NLRP3 inflammasome: a novel mechanism of atherosclerosis. Oxidative Med Cell Longev. 2019;2019:3462530.

[28] Hwang J, Qi L. Quality control in the endoplasmic reticulum: crosstalk between ERAD and UPR pathways. Trends Biochem Sci. 2018;43:593-605.

[29] Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response. Nat Rev Mol Cell Biol. 2020;21:421-438.

[30] Pfaffenbach KT, Lee AS. The critical role of GRP78 in physiologic and pathologic stress. Curr Opin Cell Biol. 2011;23:150-156.

[31] Yao Y, Lu Q, Hu Z, et al. A non-canonical pathway regulates ER stress signaling and blocks ER stress-induced apoptosis and heart failure. Nat Commun. 2017;8:133.

[32] Wang J, Hu X, Jiang H. ER stress-induced apoptosis: a novel therapeutic target in heart failure. Int J Cardiol. 2014;177:564-565.

[33] Tantisuwat L, Saengklub N, Boonpala P, et al. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation. Sci Rep. 2023;13:11472.

[34] Wang S, Binder P, Fang Q, et al. Endoplasmic reticulum stress in the heart: insights into mechanisms and drug targets. Br J Pharmacol. 2018;175:1293-1304.

[35] Hu H, Tian M, Ding C, Yu S. The C/EBP homologous protein (CHOP) transcription factor functions in endoplasmic reticulum stress-induced apoptosis and microbial infection. Front Immunol. 2019;9:3083.

[36] Koshenov Z, Oflaz FE, Hirtl M, et al. Sigma-1 receptor promotes mitochondrial bioenergetics by orchestrating ER Ca²⁺ leak during early ER stress. Metabolites. 2021;11:422.

[37] Makio T, Chen J, Simmen T. ER stress as a sentinel mechanism for ER Ca²⁺ homeostasis. Cell Calcium. 2024;124:102961.

[38] Zhang Q, Chen W, Zhang B, et al. Lonp1 and Sig-1R contribute to the counteraction of ursolic acid against ochratoxin A-induced mitochondrial apoptosis. Food Chem Toxicol. 2023;172:113592.

[39] Zhang Q, Chen W, Zhang B, et al. Central role of TRAP1 in the ameliorative effect of oleanolic acid on the mitochondrial-mediated and endoplasmic reticulum stress-excitated apoptosis induced by ochratoxin A. Toxicology. 2021;450:152681.

[40] Li Z, Guo J, Bian Y, Zhang M. Intermedin protects thapsigargin-induced endoplasmic reticulum stress in cardiomyocytes by modulating protein kinase A and sarco/endoplasmic reticulum Ca²⁺-ATPase. Mol Med Rep. 2021;23:107.

[41] Razavi HM, Hamilton JA, Feng Q. Modulation of apoptosis by nitric oxide: implications in myocardial ischemia and heart failure. Pharmacol Ther. 2005;106:147-162.

[42] Okada K, Minamino T, Tsukamoto Y, et al. Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation. 2004;110:705-712.

[43] Yang L, Wang J, Yang J, et al. Antioxidant metallothionein alleviates endoplasmic reticulum stress-induced myocardial apoptosis and contractile dysfunction. Free Radic Res. 2015;49:1187-1198.

[44] Zhang JJ, Chen JH, Zhao MP, et al. The role of endoplasmic reticulum stress in pulmonary hypertension in rat induced by chronic hypoxia and hypercapnia. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2018;34:327-333.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.